靶向治疗时代重新定义急性白血病抗真菌预防
本文综述靶向及分化治疗药物(酪氨酸激酶抑制剂、贝林妥欧单抗、奥加伊妥珠单抗、艾伏尼布、吉瑞替尼、维奈克拉)改变急性白血病治疗格局后侵袭性真菌病(IFD)流行病学的变化。此类方案缓解率更高、中性粒细胞减少更短或缺如、黏膜损伤轻微,IFD 发生率似明显降低,提示三唑类预防的旧范式可能不再适用于新方案治疗人群,需按治疗强度、骨髓毒性和药物相互作用制定风险适配的预防策略。
要点
- 靶向/分化治疗使中性粒细胞减少更短或缺如、黏膜损伤轻微,IFD 风险随之下降。
- 三唑类预防仍适用于强化化疗患者,但可能不再适用于新方案治疗者。
- 应以治疗强度、骨髓毒性和药物相互作用为依据,重新界定真正获益于初级抗真菌预防的患者。
核心结论
- 靶向治疗时代需重新界定急性白血病抗真菌预防策略,避免抗真菌药物过度暴露与研究重点错位。
研究设计与样本
- 综述性文章,围绕急性白血病靶向及分化治疗时代侵袭性真菌病流行病学变化与预防策略展开论述,未报告系统检索范围。
主要发现
- 酪氨酸激酶抑制剂、贝林妥欧单抗、奥加伊妥珠单抗、艾伏尼布、吉瑞替尼、维奈克拉等靶向药物与更高缓解率、更短或缺如的中性粒细胞减少及轻微黏膜损伤相关。
- 上述因素是IFD风险的关键决定因素,此类人群中IFD发生率似明显降低。
临床怎么用
- 对接受强化化疗的急性白血病患者,三唑类预防仍为标准。
- 对新方案治疗患者,应按治疗强度、骨髓毒性和药物相互作用进行风险分层,决定是否给予初级抗真菌预防。
局限性
- 本文为综述性论述,未报告具体研究设计、样本量及定量合并结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The therapeutic landscape of acute leukaemia (AL) has evolved profoundly with the introduction of targeted and differentiation agents, altering the epidemiology of invasive fungal disease (IFD). While antifungal prophylaxis with triazoles remains standard for patients receiving intensive chemotherapy, this paradigm may no longer apply to those treated with novel regimens. Targeted agents such as tyrosine kinase inhibitors, blinatumomab, inotuzumab ozogamycin, ivosidenib, gilteritinib, and venetoclax are associated with higher remission rates, shorter or absent neutropenia, and minimal mucosal injury-key determinants of IFD risk. As a result, the incidence of IFD appears markedly lower in such populations. Redefining antifungal prophylactic strategies must account for this therapeutic heterogeneity to avoid overexposure to antifungal drugs and misdirected research priorities. Updated, risk-adapted strategies-integrating treatment intensity, myelotoxicity, and drug interactions-are essential to define which AL patients truly benefit from primary antifungal prophylaxis in the modern era.
引用
- Nucci M, Maertens J. Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies. J Antimicrob Chemother. 2026. PMID: 41549654. doi:10.1093/jac/dkag010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。